1. Home
  2. |Experience
  3. |Corporate and Transactional
  4. |Emerging Companies and Venture Capital

Emerging Companies and Venture Capital

Overview

Today’s startups require more than vision—they needed a proven growth strategy. One that’s powered by a diverse team of trusted advisors who are immersed in the ecosystem of emerging companies and venture capital. Envisioning a practice designed to support the rapid growth and agility of emerging companies, we created GrowthStudio™. GrowthStudio powered by Crowell, offers a dedicated team of lawyers, who have collectively represented hundreds of emerging companies, venture funds, and corporate investors, throughout all investment cycles. Our roots hail from leading technology companies to leading legal services firms. We supplement our deep experience with a shared enthusiasm that comes with launching a new venture.

Entrepreneurs and early stage companies rely on sound legal and business guidance from experienced practitioners as they navigate a wide range of issues. Whether it’s the early, middle, or late stages of business growth, GrowthStudio is a one-stop-shop that collaborates with you at every stage. We meet your complex legal challenges with customized and sensible solutions, legal tools and resources, to successfully navigate through formation, capital raising, regulatory compliance, team hiring, and the evolving stages of commercialization.

Our areas of focus include:

  • Emerging Companies
  • Entrepreneur and Executive Advisory
  • Capital Needs and Financing Transactions
  • Early Stage Investors
  • Venture Capital
  • Venture Debt
  • Growth-Stage General Corporate Counseling
  • Commercial Transactions
  • Secondary Sales/Liquidity Rounds
  • Mergers & Acquisitions
  • Initial Public Offerings
  • Public Company Advisory

To learn more about our Emerging Companies and Venture Capital practice, please visit growthstudio.crowell.com.

Insights

Firm News | 1 min read | 03.11.25

Crowell & Moring Represents Nuclear Energy Startup Atomic Alchemy in its Acquisition by Oklo

March 11, 2025: Oklo Inc. (NYSE: OKLO), an advanced nuclear technology company, announced on March 5, 2025 that it has closed the $25 million acquisition of Crowell client Atomic Alchemy Inc. (“Atomic Alchemy”), a leading innovator in radioisotope production. Oklo intends to use this strategic acquisition to establish a more reliable domestic supply chain for high-value radioisotopes critical to healthcare, research, and defense sectors and provides synergies to Oklo’s fuel recycling and nuclear energy businesses. Demand for radioisotopes is expected to increase significantly over the next decade, while global supply struggles to keep pace due to aging reactor infrastructure and a fragmented global supply chain, which at present is dominated by countries outside the United States. Atomic Alchemy intends to be a low-cost U.S. radioisotope producer that can provide a secure and domestic supply of radioisotopes to U.S. companies commercializing innovative radioisotope applications. With its proprietary VIPR® technology, Atomic Alchemy is building the first scalable production facility to provide a reliable, sustainable source of high-value radioisotopes. Using a vertically integrated model and fuel recycling, in partnership with Oklo, Atomic Alchemy is transforming isotope production to address global shortages, support critical applications, and strengthen national security. The core deal team included Samuel Holland Edwards, Jon O’Connell, Justin Lurie, and Ryan Flynn....

|

Professionals

Insights

Firm News | 1 min read | 03.11.25

Crowell & Moring Represents Nuclear Energy Startup Atomic Alchemy in its Acquisition by Oklo

March 11, 2025: Oklo Inc. (NYSE: OKLO), an advanced nuclear technology company, announced on March 5, 2025 that it has closed the $25 million acquisition of Crowell client Atomic Alchemy Inc. (“Atomic Alchemy”), a leading innovator in radioisotope production. Oklo intends to use this strategic acquisition to establish a more reliable domestic supply chain for high-value radioisotopes critical to healthcare, research, and defense sectors and provides synergies to Oklo’s fuel recycling and nuclear energy businesses. Demand for radioisotopes is expected to increase significantly over the next decade, while global supply struggles to keep pace due to aging reactor infrastructure and a fragmented global supply chain, which at present is dominated by countries outside the United States. Atomic Alchemy intends to be a low-cost U.S. radioisotope producer that can provide a secure and domestic supply of radioisotopes to U.S. companies commercializing innovative radioisotope applications. With its proprietary VIPR® technology, Atomic Alchemy is building the first scalable production facility to provide a reliable, sustainable source of high-value radioisotopes. Using a vertically integrated model and fuel recycling, in partnership with Oklo, Atomic Alchemy is transforming isotope production to address global shortages, support critical applications, and strengthen national security. The core deal team included Samuel Holland Edwards, Jon O’Connell, Justin Lurie, and Ryan Flynn....